tetano
Editor, Senior Moderator
J Gen Virol
. 2022 Jan;103(1).
doi: 10.1099/jgv.0.001698.
Selection and T-cell antigenicity of synthetic long peptides derived from SARS-CoV-2
Katarzyna Piadel[SUP] 1 [/SUP], Amin Haybatollahi[SUP] 1 [/SUP], Angus George Dalgleish[SUP] 1 [/SUP], Peter Lawrence Smith[SUP] 1 [/SUP]
Affiliations
Abstract
The pandemic caused by SARS-CoV-2 has led to the successful development of effective vaccines however the prospect of variants of SARS-CoV-2 and future coronavirus outbreaks necessitates the investigation of other vaccine strategies capable of broadening vaccine mediated T-cell responses and potentially providing cross-immunity. In this study the SARS-CoV-2 proteome was assessed for clusters of immunogenic epitopes restricted to diverse human leucocyte antigen. These regions were then assessed for their conservation amongst other coronaviruses representative of different alpha and beta coronavirus genera. Sixteen highly conserved peptides containing numerous HLA class I and II restricted epitopes were synthesized from these regions and assessed in vitro for their antigenicity against T-cells from individuals with previous SARS-CoV-2 infection. Monocyte derived dendritic cells were generated from these peripheral blood mononuclear cells (PBMC), loaded with SARS-CoV-2 peptides, and used to induce autologous CD4+ and CD8+ T cell activation. The SARS-CoV-2 peptides demonstrated antigenicity against the T-cells from individuals with previous SARS-CoV-2 infection indicating that this approach holds promise as a method to activate anti-SAR-CoV-2 T-cell responses from conserved regions of the virus which are not included in vaccines utilising the Spike protein.
Keywords: SARS-CoV-2; T-cells; peptide; vaccine.
. 2022 Jan;103(1).
doi: 10.1099/jgv.0.001698.
Selection and T-cell antigenicity of synthetic long peptides derived from SARS-CoV-2
Katarzyna Piadel[SUP] 1 [/SUP], Amin Haybatollahi[SUP] 1 [/SUP], Angus George Dalgleish[SUP] 1 [/SUP], Peter Lawrence Smith[SUP] 1 [/SUP]
Affiliations
- PMID: 35014605
- DOI: 10.1099/jgv.0.001698
Abstract
The pandemic caused by SARS-CoV-2 has led to the successful development of effective vaccines however the prospect of variants of SARS-CoV-2 and future coronavirus outbreaks necessitates the investigation of other vaccine strategies capable of broadening vaccine mediated T-cell responses and potentially providing cross-immunity. In this study the SARS-CoV-2 proteome was assessed for clusters of immunogenic epitopes restricted to diverse human leucocyte antigen. These regions were then assessed for their conservation amongst other coronaviruses representative of different alpha and beta coronavirus genera. Sixteen highly conserved peptides containing numerous HLA class I and II restricted epitopes were synthesized from these regions and assessed in vitro for their antigenicity against T-cells from individuals with previous SARS-CoV-2 infection. Monocyte derived dendritic cells were generated from these peripheral blood mononuclear cells (PBMC), loaded with SARS-CoV-2 peptides, and used to induce autologous CD4+ and CD8+ T cell activation. The SARS-CoV-2 peptides demonstrated antigenicity against the T-cells from individuals with previous SARS-CoV-2 infection indicating that this approach holds promise as a method to activate anti-SAR-CoV-2 T-cell responses from conserved regions of the virus which are not included in vaccines utilising the Spike protein.
Keywords: SARS-CoV-2; T-cells; peptide; vaccine.